Cianergoline is an ergoline derivative with marked dopaminergic agonist and a predominant cardiovascular action patented by Farmitalia Carlo Erba S.p.A for hypertension treatment. The preclinical evaluation shows dose-related hypotensive effects after single oral, intraduodenal and intravenous administration of Cianergoline in cats, dogs, and rats. Cianergoline showed a prompt onset of action and a prolonged effect on blood pressure at low doses without substantially modifying animals heart rate. One month daily oral administration of Cianergoline in rats produced an antihypertensive effect persisting through the entire experiment with no signs of tachyphylaxis. Unfortunately, in clinical trials Cianergoline caused a slight, statistically non-significant blood pressure lowering effect in patients with essential hypertension and does not modify the release of prolactin, lipid metabolism or the basal activity or postural responsiveness of the renin-angiotensin-aldosterone axis and of the sympathetic nervous system.